Iqvia (IQV) versus Crispr Therapeutics (CRSP) Critical Contrast

Crispr Therapeutics (NASDAQ: CRSP) and Iqvia (NYSE:IQV) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.


This table compares Crispr Therapeutics and Iqvia’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Crispr Therapeutics -466.58% -38.42% -25.26%
Iqvia 0.58% 12.60% 4.65%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Crispr Therapeutics and Iqvia, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Crispr Therapeutics 0 3 3 0 2.50
Iqvia 0 7 9 0 2.56

Crispr Therapeutics currently has a consensus price target of $22.81, indicating a potential downside of 23.27%. Iqvia has a consensus price target of $107.53, indicating a potential upside of 7.61%. Given Iqvia’s stronger consensus rating and higher probable upside, analysts plainly believe Iqvia is more favorable than Crispr Therapeutics.

Valuation and Earnings

This table compares Crispr Therapeutics and Iqvia’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Crispr Therapeutics $5.16 million 264.40 -$23.17 million ($0.32) -92.91
Iqvia $6.88 billion 3.02 $115.00 million $0.29 344.55

Iqvia has higher revenue and earnings than Crispr Therapeutics. Crispr Therapeutics is trading at a lower price-to-earnings ratio than Iqvia, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

21.9% of Crispr Therapeutics shares are held by institutional investors. Comparatively, 95.8% of Iqvia shares are held by institutional investors. 40.0% of Crispr Therapeutics shares are held by company insiders. Comparatively, 6.4% of Iqvia shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.


Iqvia beats Crispr Therapeutics on 11 of the 13 factors compared between the two stocks.

Crispr Therapeutics Company Profile

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell. The location at which the Cas9 molecular scissors cut the DNA to be edited is specified by guide ribonucleic acid (RNA), which is comprised of a crRNA component and a tracrRNA component, either individually or combined together as a single guide RNA. The Company has business operations in London, the United Kingdom, as well as research and development operations in Cambridge, the United States.

Iqvia Company Profile

IQVIA Holdings Inc., formerly Quintiles IMS Holdings, Inc., provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services. The Research & Development Solutions segment provides biopharmaceutical development services. It offers project management and clinical monitoring, clinical trial support services, Q2 solutions, and strategic planning and design. The Integrated Engagement Services segment offerings include healthcare provider engagement services, patient engagement services, and scientific strategy and medical affairs services. The Company has its operations in the Americas, Europe and Africa, and the Asia-Pacific.

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply